Title : A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.

Pub. Date : 2015 Feb

PMID : 25537627






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dose-dependent increase in plasma orteronel concentrations was indicated over the 200-400 mg BID dose range. orteronel BH3 interacting domain death agonist Homo sapiens
2 CONCLUSIONS: Orteronel at doses up to 400 mg BID was tolerable in Japanese CRPC patients. orteronel BH3 interacting domain death agonist Homo sapiens